Information for patients on availability of new weight loss treatment

From Monday 23 June, a new weight loss drug called tirzepatide, sometimes referred to as Mounjaro, will start becoming available for use in primary care settings.

In line with NHS England guidance, this treatment will only be available for patients whose body mass index is above 40 and have been diagnosed with four or more obesity-related health conditions*.

Patients are advised that prescriptions will not be provided immediately, and that 23 June is the date from which GPs may wish to begin a discussion with eligible patients about using tirzepatide as part of their overall weight-loss journey.

Access will be prioritised for those with the greatest clinical need, as the treatment is intended to support people living with health conditions caused or made worse by obesity.

Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board is currently working with colleagues in primary care to ensure this new treatment is offered to those patients who fulfil this criteria.

At this time, patients are kindly asked not to contact their GP practice with requests for weight loss treatment.

All patients, including those who may be eligible for the new drug, are continued to be encouraged to access NHS Support Healthy Living Initiatives, such as diet support and activity groups, as part of their overall weight loss journey.

To be eligible for tirzepatide, patients need to have a body mass index (BMI) above 40 and have been diagnosed with four or more of the following conditions:

• Type 2 diabetes
• Hypertension
• Cardiovascular disease
• Obstructive sleep apnoea
• Dyslipidaemia